Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.71 |
| ▸ | RARB | P10826 | 7/20 | 0.44 |
| ▸ | RARG | P13631 | 7/20 | 0.44 |
| ▸ | RARA | P10276 | 5/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 4/20 | 0.42 |
| ▸ | RXRB | P28702 | 3/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019867 | 0.90 | CNR2 (0.71) | CNR2RARBRARGRARALTB4R | |
| SCHEMBL3020426 | 0.89 | CNR2 (0.58) | CNR2RARBRARGRARARXRA | |
| SCHEMBL3019768 | 0.88 | CNR2 (0.58) | CNR2RARBRARGRARARXRA | |
| SCHEMBL3021003 | 0.88 | CNR2 (0.66) | CNR2RARBRARGALDH1A1KDM4E | |
| SCHEMBL3017974 | 0.87 | CNR2 (0.78) | CNR2RARBRARGRARALTB4R | |
| SCHEMBL3016208 | 0.84 | CNR2 (1.00) | CNR2ALDH1A1MAPK1KDM4ENPC1 | |
| SCHEMBL17889676 | 0.84 | CNR2 (1.00) | CNR2ALDH1A1MAPK1KDM4ENPC1 | |
| SCHEMBL15428814 | 0.84 | CNR2 (1.00) | CNR2ALDH1A1MAPK1KDM4ENPC1 | |
| SCHEMBL13211747 | 0.84 | CNR2 (0.67) | CNR2ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL3014661 | 0.83 | CNR2 (1.00) | CNR2ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735239-B1 | ORAL CANNABINOID RECEPTOR MODULATOR FORMULATIONS | CLEVELAND CLINIC FOUND (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250082624-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENT | NeuroTherapia, Inc. | 2025-03-13 | — | — | US | disclosed |
| WO-2025054408-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENT | NeuroTherapia, Inc. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20230404990-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CLEVELAND CLINIC FOUND (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220047568-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CLEVELAND CLINIC FOUND (US) | 2022-02-17 | — | — | US | disclosed |
| US-11160798-B2 | Neuroprotective CB2 receptor agonists | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-10835521-B2 | Neuroprotective CB2 receptor agonists | THE CLEVELAND CLINIC FOUNDATION (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200085811-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | THE CLEVELAND CLINIC FOUNDATION | 2020-03-19 | — | — | US | disclosed |
| US-9394267-B2 | Heterocyclic modulators of cannabinoid receptors | THE CLEVELAND CLINIC FOUNDATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160193201-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | THE CLEVELAND CLINIC FOUNDATION | 2016-07-07 | — | — | US | disclosed |
| US-20150148408-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-05-28 | — | — | US | disclosed |
| EP-2872138-A2 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014011949-A2 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2014-01-16 | — | — | WO | disclosed |
| EP-2178371-B1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | UNIV TEXAS (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130237536-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8440832-B2 | Heterocyclic modulators of cannabinoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-14 | — | — | US | disclosed |
| US-20100204220-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-08-12 | — | — | US | disclosed |
| CN-101801187-A | heterocyclic modulators of cannabinoid receptors | UNIV TEXAS | 2010-08-11 | — | — | CN | disclosed |
| EP-2178371-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | Board of Regents, The University of Texas System (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012221-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204220-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885RARB 817/4885RARG 630/4885 |
| US-11160798-B2 | Neuroprotective CB2 receptor agonists | CNR1, CNR2, CHRNA2 | CNR2 2/4885RARB 1035/4885RARG 1629/4885 |
| US-20130237536-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885RARB 817/4885RARG 630/4885 |
| US-20250082624-A1 | METHODS OF TREATING COGNITIVE IMPAIRMENT | CHAT, NLN, NEFM | CNR2 1188/4885RARB 3028/4885RARG 2489/4885 |
| US-10835521-B2 | Neuroprotective CB2 receptor agonists | CNR1, CNR2, CHRNA2 | CNR2 2/4885RARB 885/4885RARG 1277/4885 |
| US-20220047568-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CNR1, CNR2, CHRNA2 | CNR2 2/4885RARB 911/4885RARG 1561/4885 |
| US-20200085811-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CNR1, CNR2, CHRNA2 | CNR2 2/4885RARB 1106/4885RARG 1790/4885 |
| US-20160193201-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CNR1, CNR2, CHRNA2 | CNR2 2/4885RARB 885/4885RARG 1277/4885 |
| US-20150148408-A1 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS | CNR1, CNR2, GPR18 | CNR2 2/4885RARB 817/4885RARG 630/4885 |
| US-20230404990-A1 | NEUROPROTECTIVE CB2 RECEPTOR AGONISTS | CNR1, CNR2, CHRNA2 | CNR2 2/4885RARB 707/4885RARG 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.